View Older Stories

May 19, 2026 02:16PM ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

May 19, 2026 07:31AM ImmunityBio presents bladder cancer treatment comparison data at AUA

May 18, 2026 03:02PM $IBRX DEADLINE: Immunitybio Inc. Investors Who Lost Money Should Contact Block & Leviton Before May 26th Deadline

May 18, 2026 01:01PM ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

May 18, 2026 07:31AM ImmunityBio receives five US patents for cancer drug combination

May 7, 2026 07:39AM ImmunityBio, Inc. (IBRX) Misses Q1 EPS by 55c

Apr 21, 2026 07:30AM ImmunityBio launches ANKTIVA cancer treatment in Saudi Arabia

Apr 9, 2026 07:31AM ImmunityBio reports Q1 revenue of $44 million, up 168% year-over-year

Apr 6, 2026 07:30AM ImmunityBio responds to FDA concerns over promotional materials

Mar 31, 2026 07:31AM ImmunityBio secures $100 million in financing with debt conversion

Mar 30, 2026 03:21PM ImmunityBio ALERT: $IBRX Investors Who Lost Money Should Contact Block & Leviton By May 26th To Potentially Recover Losses

Mar 26, 2026 07:30AM ImmunityBio bladder cancer trial meets statistical power requirements

Mar 24, 2026 12:52PM BTIG on Immunitybio Inc (IBRX): FDA warning letter issue 'likely resolvable,' selloff a buying oppty

Mar 24, 2026 10:44AM ImmunityBio shares plunge after FDA warning over misleading ads

Mar 24, 2026 09:27AM FDA issues warning letter to ImmunityBio over misleading ANKTIVA ads

Mar 20, 2026 01:08PM ImmunityBio receives approval for ANKTIVA in Macau for bladder cancer

Mar 17, 2026 07:31AM NCCN updates bladder cancer guidelines to include ImmunityBio's ANKTIVA

Mar 13, 2026 07:30AM ImmunityBio completes NK cell manufacturing programs with 74 subjects

Mar 11, 2026 04:11PM BTIG Assumes Immunitybio Inc (IBRX) at Buy

Mar 9, 2026 07:31AM ImmunityBio resubmits cancer treatment application to FDA

Mar 4, 2026 07:54AM Immunitybio Inc (IBRX) PT Raised to $12 at Piper Sandler

Feb 26, 2026 07:31AM ImmunityBio completes enrollment in bladder cancer trial ahead of schedule

Feb 25, 2026 03:09PM ImmunityBio (IBRX) January 5.5 puts active as share price down 14.5%

Feb 23, 2026 01:03PM Immunitybio Inc (IBRX) PT Raised to $15 at H.C. Wainwright

Feb 23, 2026 10:39AM Increasing unusual put option volume: FND BRBR XRX FSLY XLP LNC HBAN FEZ OKTA VICI VTRS IGV IBRX

Feb 23, 2026 08:17AM ImmunityBio, Inc. (IBRX) Tops Q4 EPS by 5c

Feb 23, 2026 07:01AM ImmunityBio reports 700% revenue growth, expands approvals globally

Feb 20, 2026 08:30AM ImmunityBio partners to launch ANKTIVA cancer drug in Saudi Arabia

Feb 19, 2026 09:02AM ImmunityBio partners with Accord Healthcare for European ANKTIVA launch

Feb 18, 2026 09:01AM ImmunityBio wins European approval for bladder cancer treatment

Feb 17, 2026 06:09AM ImmunityBio discusses drug approvals with Saudi regulators

Jan 26, 2026 06:49AM Immunitybio Inc (IBRX) PT Raised to $10 at H.C. Wainwright

Jan 23, 2026 07:00AM ImmunityBio reports survival data from glioblastoma trial

Jan 22, 2026 01:17PM Immunitybio Inc (IBRX) PT Raised to $9 at BTIG

Jan 21, 2026 10:09AM Increasing unusual call option volume: SAVA GORO IBRX VET XP IGV MRAM RMBS ONON BLDP

Jan 20, 2026 07:44AM Immunitybio Inc (IBRX) PT Raised to $7 at Piper Sandler

Jan 16, 2026 10:44AM Increasing unusual option volume: IRE IBRX QNCX FE IREX RVMD RPD

Jan 16, 2026 07:00AM ImmunityBio reports 15-month response in lymphoma cell therapy trial

Jan 16, 2026 07:00AM ImmunityBio reports progress in bladder cancer trial enrollment

Jan 15, 2026 08:41AM ImmunityBio releases preliminary 2025 financial results

Jan 15, 2026 08:32AM ImmunityBio reports $113 million revenue, 700% annual increase

Jan 14, 2026 08:30AM ImmunityBio gets Saudi approval for bladder cancer treatment ANKTIVA

Jan 13, 2026 08:30AM ImmunityBio reports positive lung cancer trial results for ANKTIVA

Dec 29, 2025 06:04AM ImmunityBio amends stock sale agreement to authorize $460M offering

Dec 21, 2025 04:00AM Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026

Dec 16, 2025 09:01AM ImmunityBio's ANKTIVA shows 96% survival in bladder cancer study

Dec 12, 2025 11:37AM Immunitybio Inc (IBRX) PT Raised to $9 at Jefferies

Dec 12, 2025 06:10AM ImmunityBio gets european drug agency nod for bladder cancer treatment

Nov 5, 2025 01:58AM ImmunityBio, Inc. (IBRX) Tops Q3 EPS by 4c

Sep 10, 2025 07:30AM H.C. Wainwright Reiterates Buy Rating on Immunitybio Inc (IBRX)

View Older Stories